Dupilumab: a review of its use in the treatment of atopic dermatitis
MJ Gooderham, HC Hong, P Eshtiaghi… - Journal of the American …, 2018 - Elsevier
Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis
characterized by a T helper 2 (Th2) immune response phenotype and may be associated
with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that
inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-
4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the
United States and Europe for the treatment of adult patients with moderate-to-severe AD …
characterized by a T helper 2 (Th2) immune response phenotype and may be associated
with systemic inflammation. Dupilumab is an interleukin 4 (IL-4) receptor α-antagonist that
inhibits IL-4 and IL-13 signaling through blockade of the shared IL-4α subunit. Blockade of IL-
4/13 is effective in reducing Th2 response. Dupilumab has recently been approved in the
United States and Europe for the treatment of adult patients with moderate-to-severe AD …